Finally, expression and/or activity of AKT, ERK/MEK, and/or SYK could be investigated as potential prognostic factors in predicting sensitivity/resistance to EGFR inhibitor treatment in TNBC patients as is being undertaken in NSCLC [85,86,87]. The gene discussed is MAPK1; the disease is non-small cell lung carcinoma.